
Opinion|Videos|February 27, 2025
BCG for treatment of NMIBC
Experts discuss the use of bacille Calmette-Guérin (BCG) as the standard treatment for high-risk non–muscle-invasive bladder cancer (NMIBC), when a patient is considered unresponsive to BCG, and how BCG shortages have impacted clinical practice and urologists in the community.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- BCG has long been the standard treatment for high-risk NMIBC.
- When do you consider a patient to be unresponsive to BCG?
- How have BCG shortages impacted your practice/urologists in the community
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Unmet needs and emerging solutions in MRI-guided prostate cancer care
2
HHS requests testosterone therapy label updates, citing new safety data
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5













